276 related articles for article (PubMed ID: 29525182)
1. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
[TBL] [Abstract][Full Text] [Related]
2. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
Kiszka-Kanowitz M; Theede K; Mertz-Nielsen A
Scand J Gastroenterol; 2016 Dec; 51(12):1470-1475. PubMed ID: 27686002
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
Ansari A; Elliott T; Baburajan B; Mayhead P; O'Donohue J; Chocair P; Sanderson J; Duley J
Aliment Pharmacol Ther; 2008 Sep; 28(6):734-41. PubMed ID: 19145729
[TBL] [Abstract][Full Text] [Related]
6. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Leong RW; Gearry RB; Sparrow MP
Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
[TBL] [Abstract][Full Text] [Related]
7. Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
Kreijne JE; de Veer RC; de Boer NK; Dijkstra G; West R; Moorsel SAW; de Jong DJ; van der Woude CJ; de Vries AC;
Aliment Pharmacol Ther; 2019 Aug; 50(4):407-415. PubMed ID: 31359480
[TBL] [Abstract][Full Text] [Related]
8. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.
Min MX; Weinberg DI; McCabe RP
J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
Vasudevan A; Con D; De Cruz P; Sparrow MP; Friedman AB; Garg M; Kashkooli S; Gibson PR; van Langenberg DR
Aliment Pharmacol Ther; 2024 Feb; 59(4):504-514. PubMed ID: 38095246
[TBL] [Abstract][Full Text] [Related]
10. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
Thomsen SB; Allin KH; Burisch J; Jensen CB; Hansen S; Gluud LL; Theede K; Kiszka-Kanowitz M; Nielsen AM; Jess T
United European Gastroenterol J; 2020 Feb; 8(1):68-76. PubMed ID: 32213059
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
[TBL] [Abstract][Full Text] [Related]
12. Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study.
Pavlidis P; Stamoulos P; Abdulrehman A; Kerr P; Bull C; Duley J; Ansari A
Inflamm Bowel Dis; 2016 Jul; 22(7):1639-46. PubMed ID: 27271488
[TBL] [Abstract][Full Text] [Related]
13. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.
Govani SM; Higgins PD
J Crohns Colitis; 2010 Oct; 4(4):444-9. PubMed ID: 21122542
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
Serpico MR; Maltz R; Crandall W; Bricker J; Dotson JL; Kim SC; Boyle B
J Pediatr Gastroenterol Nutr; 2018 Sep; 67(3):341-345. PubMed ID: 29601433
[TBL] [Abstract][Full Text] [Related]
15. Successful Pregnancies with Thiopurine-Allopurinol Co-Therapy for Inflammatory Bowel Disease.
Sheikh M; Nelson-Piercy C; Duley J; Florin T; Ansari A
J Crohns Colitis; 2015 Aug; 9(8):680-4. PubMed ID: 25939351
[TBL] [Abstract][Full Text] [Related]
16. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
[TBL] [Abstract][Full Text] [Related]
17. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
Wall GC; Muktar H; Effken C; Mahajan PB
Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
[TBL] [Abstract][Full Text] [Related]
18. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
[TBL] [Abstract][Full Text] [Related]
19. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
[TBL] [Abstract][Full Text] [Related]
20. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
Smith MA; Blaker P; Marinaki AM; Anderson SH; Irving PM; Sanderson JD
J Crohns Colitis; 2012 Oct; 6(9):905-12. PubMed ID: 22386736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]